Enterprise record

Aprea Therapeutics, Inc. logo

Aprea Therapeutics, Inc.

Public governance Claims and source records for this enterprise.

Follow
More
Reports & analysis (Directory temporarily unavailable)Alpha EvalSave PDFCompareChallenge a ClaimClaim this record

Alpha ID: alpha:company:68f16ebf-7ad9-4519-b954-411bfa976e6cVersion: public-1As of: unavailable

19 published Claims3 sources

Key Claims

Board and committees

Source-backed public-market identity

Index memberships

Current memberships are attached to a specific security and listing. Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.

No current membership is published in Alpha's tracked index universe.

This is not evidence that the company is absent from every market index.

As of Sep 29, 2026. Rights-filtered public evidence only; no redistribution or model training is granted.

Only source-backed memberships with an explicit public redistribution basis are returned.

Evidence, history and coverage

Additional published Claims

Published evidence records

3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Alpha canonical company public projection

    canonical identity · Source published: Date unavailable · Retrieved: Sep 29, 2026

    Supports 3 claims
    • Legal Name: Aprea Therapeutics, Inc. · Claim reviewed: Sep 29, 2026
    • Entity Status: Public listing published · Claim reviewed: Sep 29, 2026
    • Published Fact: US · Claim reviewed: Sep 29, 2026

  2. SEC DEF 14A 0001104659-26-052044

    sec def 14a · Source published: Apr 30, 2026 · Retrieved: Sep 6, 2026

    Supports 8 claims
    • Leadership Role: Richard Peters, M.D., Ph.D.: Chairman of the Board · Claim reviewed: Sep 29, 2026
    • Leadership Role: Bernd R. Seizinger, M.D., Ph.D.: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Gabriela Gruia, M.D.: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Jean-Pierre Bizzari, M.D.: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Oren Gilad, Ph.D.: President, Chief Executive Officer and Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Rifat Pamukcu, M.D.: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: John P. Hamill: Senior Vice President, Chief Financial Officer and Secretary · Claim reviewed: Sep 29, 2026
    • Leadership Role: Oren Gilad, Ph.D.: President and Chief Executive Officer · Claim reviewed: Sep 29, 2026

  3. DEF 14A apre-20260616xdef14a.htm

    sec proxy · Source published: Apr 30, 2026 · Retrieved: Sep 2, 2026

    Supports 8 claims
    • Leadership Role: Bernd R. Seizinger: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Gabriela Gruia: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Jean-Pierre Bizzari: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: John B. Henneman III: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Marc Duey: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Michael Grissinger: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Richard Peters: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Rifat Pamukcu: Director · Claim reviewed: Sep 29, 2026